PC945

PC945, a potent, long-acting antifungal triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus . PC945 is also a potent, tightly binding inhibitor of A. fumigatus sterol 14α-demethylase activity, CYP51A and CYP51B , with IC 50 s of 0.23 μM and 0.22 μM, respectively In Vitro PC945 is a triazole antifungal designed for administration via inhalation. PC945 exhibits the most potent antifungal activity on azole-susceptible strain NCPF2010 with the MIC value of 0.063 µg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PC945 (0.56-14 μg/mouse; intranasal; daily for 7 days) substantially inhibits the incidence of rolling behavior . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Specific-pathogen-free A/J mice (male, 5 weeks old, pulmonary Aspergillus infection) Dosage: 0.56, 2.8, 14 μg/mouse (intranasal application of 0.016-, 0.08-, and 0.4-mg/ml suspensions, respectively) Administration: Intranasal; daily for 7 days Result: Substantially inhibited the incidence of rolling behavior. IC50& Target:fungal CYP51A 0.23 μM (IC 50 ) CYP51B 0.22 μM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet